BRAF-positive non-small cell lung cancer (NSCLC) treatments can use the BRAF biomarker to provide effective, targeted treatment for this subset of lung cancer. BRAF-positive NSCLC is an uncommon or ...
Nurix Therapeutics, Inc. presented promising preclinical data at the AACR 2025 Annual Meeting, showcasing their innovative targeted protein degradation medicines aimed at addressing various cancers, ...
Nurix's lead BTK degrader, bexobrutideg, demonstrates exceptional efficiency, with a single molecule degrading approximately 10,000 copies of BTK per hour BRAF degrader demonstrates broad activity ...
C4 Therapeutics is sawing off another part of its solely owned pipeline, this time ending work on its clinical-stage BRAF degrader program in order to focus on its IKZF1/3 degrader cemsidomide. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback